StarRay Therapeutics

StarRay Therapeutics, often operating under the brand C Ray Therapeutics, is a clinical-stage biotechnology company specializing in the discovery and development of next-generation radiopharmaceuticals and radionuclide drug conjugates (RDCs). Headquartered in Chengdu, China, the company maintains a comprehensive infrastructure for targeted ligand discovery, early-stage research, and large-scale cGMP manufacturing of radioligand therapies. Its pipeline is headlined by targeted alpha and beta therapies for prostate cancer, specifically assets targeting the prostate-specific membrane antigen (PSMA) like 225Ac-PSMA-CY313 and 177Lu-PSMA-0057. StarRay also functions as a specialized CRDMO, providing end-to-end solutions for the radiopharmaceutical industry, including process development and complex radionuclide logistics. The company is notably backed by major life science investors such as 6 Dimensions Capital and focuses on addressing unmet needs in oncology through precision theranostics.